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Abstract: More than half a century after their discovery, benzodiazepines (BDZs) still represent 
one of the largest and most widely prescribed groups of psychotropic compounds, not only in 
clinical psychiatry but also in the entire medical field. Over the last two decades, however, 
there has been an increased focus on the development of antidepressants and antipsychotics on 
the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in 
BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, 
medical students, nurses, and other mental health professionals might receive poor academic 
teaching and training regarding these agents, and have the false impression that BDZs represent 
an outdated chapter in clinical psychopharmacology. However, recent advances in the field, 
including findings concerning epidemiology, addiction risk, and drug interactions, as well as 
the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in 
clinical practice. During a recent thematic event convened with the aim of approaching this topic 
in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws 
in current teaching pathways, identify the main clinical pros and cons regarding current use of 
BDZs in clinical practice, and provide an updated overview of their use across specific clinical 
areas and patient populations. The main results are presented and discussed in this review.
Keywords: benzodiazepines, psychiatric clinical practice, teaching issues, risks and benefits
Introduction
After the discovery of chlordiazepoxide in the late 1950s by Leo Sternbach, 
benzodiazepines (BDZs) became widely available, being prescribed to hundreds of mil-
lions of patients in various medical settings. Their high therapeutic index, availability 
of the antagonist flumazenil in case of overdose, and their rapid onset of action make 
these compounds particularly versatile and difficult to replace in clinical psychiatry.
Over recent years, there have been advances in our knowledge of the risks and 
benefits of BDZs along with the development of molecules with novel mechanisms of 
drug release. Therefore, clinicians have the unprecedented opportunity to weigh the 
pros and cons of prescribing BDZs for different patients, recognize red flags of abuse 
early, and detect risk factors for potential misuse on the basis of the patient’s attitude, 
personality, and pathological behavior, even before prescribing such compounds.1 In 
addition, knowledge about differential abuse liability of various BDZs2 and interac-
tion with other drugs,3 substances,4 and alcohol5,6 should enable more informed and 
appropriate prescription of BDZs.
Currently, BDZs are routinely and widely used in the treatment of a number of 
psychiatric conditions, are the pharmacological mainstay of the clinical management 
of anxiety and sleep disorders, and are an add-on therapy for schizophrenia and other 
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psychotic disorders. However, specific pharmacological 
features of BDZs may be responsible for their uncontrolled 
and non- evidence-based use with the potential for abuse and 
misuse and the controversy regarding these agents in the psy-
chiatric community. The actual prevalence of use of BDZs in 
the general population and in psychiatric patients is difficult to 
determine, since prescription of these drugs depends on sev-
eral contextual factors, including mental health professionals’ 
prescribing habits and patients’ socio-demographic charac-
teristics, such as age, gender, presence of comorbidities, etc.7 
In particular, the risks of dependence and impaired cognitive 
functioning associated with their unrestricted long-term use 
need to be balanced against the benefits that, in many cases, 
follow from short or intermittent use of BDZs.7–9 Moreover, 
widespread prescription of BDZs, the related abuse risk, and 
the side effect profile, particularly in specific populations (eg, 
pregnancy, the elderly), should encourage implementation of 
specific training interventions in order to minimize the risk of 
misuse by patients and the risk of malpractice for prescribers. 
It is worthwhile reviewing these issues in order to resolve the 
possible mismatch between education in psychopharmacology 
and use of psychotropics in clinical practice.
One potential explanation for the current misuse of BDZs 
is the lack of specific education provided for residents in 
psychiatry on traditional pharmacological treatments, such 
as lithium, tricyclic antidepressants, first-generation anti-
psychotics, and BDZs.10 For instance, at the end of residency, 
more recently developed psychotropic drugs with a more ver-
satile profile of action and a more favorable side effect profile 
tend to be dispensed11 in preference to older compounds.12 
Following on from this observation, a recent meta-analysis 
showed that implementation of brief interventions regarding 
effective and efficient strategies for BDZ management were 
particularly useful in clinical practice.13
In order to critically revise the current state of the art 
regarding use of BDZs in clinical practice from the perspec-
tive of a group of young academic clinicians, the present 
review sought to: provide an updated overview of BDZ use 
in various psychiatric disorders and populations; highlight the 
need of modern psychiatrists and mental health professionals 
for education on BDZs; and clarify potential controversies 
concerning the use of BDZs in clinical practice.
Methods
Literature pertinent to this narrative review was sought using 
PubMed/Medline, the ISI Web of Knowledge, Google Scholar, 
and Cochrane Library using a multi-step  methodology. 
Only papers written in English, published in peer- 
reviewed journals, and related to use of BDZs in clinical 
psychiatry were included in the review. Papers were 
excluded if they: investigated use of BDZs in children or 
in animal models; were case reports or non-clinical stud-
ies; or investigated use of non-BZD sedatives, hypnotics, 
and anxiolytics. First, a search was carried out with the 
keyword “benzodiazepine” variably combined with the 
terms “anxiety disorders”, “obsessive-compulsive disorder”, 
“post-traumatic stress disorder”, “acute stress disorder”, 
“affective disorders”, “mood disorders”, “depressive dis-
orders”, “bipolar disorders”, “suicide”; “schizophrenia”, 
“psychoses”, “neuroleptic-induced akathisia”, “neurolep-
tic-induced tardive dyskinesia”, “addictions”, “substance 
use disorders”, “dual diagnosis”, “delirium”, “alcohol 
withdrawal”, “impulse control disorders”, “impulsivity”, 
“aggression”, “personality disorders”, “eating disorders”; 
“oncology”, “cancer”, “consultation-liaison”, “migrants”, 
and “elderly”. A second search targeted the area of “adverse 
effects of BDZs” by using the keyword “benzodiazepine” 
variably combined with the terms “side effects”, “toler-
ability”, “adverse events”, “pregnancy”, “teratogenicity”, 
and “breastfeeding”. The third search included the term 
“benzodiazepines” combined with the terms “education”, 
“training”, “post-graduate training”, “university degree 
course”, and “residency”.
The publication search included meta-analyses, random-
ized controlled trials (RCTs), naturalistic and retrospective 
studies, and clinical reviews. When several papers were 
available from a specific RCT, only the pivotal trials were 
reviewed. Studies not cited in meta-analyses, recent clinical 
reviews, or guidelines were included in the analysis.
A manual search for reference lists from articles selected 
in the primary search and for any relevant reviews was 
also done. Additional information was sought in recently 
published international guidelines on treatment using 
BDZs.
Three authors (BD, UA, AF) independently evaluated 
the results of the search, identified all potentially relevant 
papers (including guidelines when present), and supervised 
the review for each topic. All the authors, on the basis of 
their specific area of expertise, discussed the results during 
a thematic event.
Results
The initial database search revealed a total of 41,719 papers. 
Of these, 40,998 were excluded on the basis of title and 
abstract screen. The full text of the remaining 721 papers 
was examined in detail. In total, 512 articles were excluded 
as duplicates because they involved children or because their 
results were included in meta-analyses or clinical reviews. 
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A total of 209 papers constituted the final records included 
in the present narrative review. The results are subdivided 
in four sections, each dealing with different clinical condi-
tions/populations, as follows: use of BDZs in obsessive–
compulsive disorder, post-traumatic stress disorder, anxiety 
disorders, psychosomatic disorders, and sleep disorders; use 
of BDZs in primary psychoses and depressive disorders; 
use of BDZs in impulse control, personality, eating and 
addictive disorders (dual diagnosis and novel psychoactive 
substance [NPS] abuse); and use of BDZs in special patient 
populations.
Use of BDZs in OCD, PTSD, anxiety, 
psychosomatic and sleep disorders
Obsessive–compulsive disorder
Evidence for beneficial effects of BDZs as monotherapy for 
the treatment of obsessive–compulsive disorder (OCD) is 
poor and primarily limited to case series, with the available 
reports dealing exclusively with clonazepam and alprazolam. 
The results of double-blind studies with clonazepam are 
controversial,14,15 and an open trial with alprazolam16 did not 
support the efficacy of BDZs for OCD or anxiety symptoms. 
Based on these data, BDZs cannot be recommended currently 
as monotherapy for OCD.17
Adjunctive lorazepam in treatment-resistant OCD patients 
did not result in any beneficial effect over placebo.18 Moreover, 
clonazepam, did not have a greater or more rapid anxiolytic 
effect than sertraline in a double-blind, placebo-controlled 
study in OCD patients.19 Therefore, adjunctive BDZs cannot 
be recommended as an effective therapy for OCD patients.
Notwithstanding the limited evidence for the efficacy of 
BDZs as adjunctive therapy in patients with OCD, these com-
pounds are widely used in clinical practice, with up to 25% 
of patients being prescribed BDZs as augmenting agents.20 
This finding highlights the perception of clinicians that BDZs 
are useful add-on treatments for OCD patients, at least at 
the start of treatment with a selective serotonin reuptake 
inhibitor (SSRI). Although international guidelines discour-
age the use of BDZs as monotherapy or as part of combined 
treatment for OCD, modest doses of BDZs may be used to 
relieve anxiety and distress in patients with OCD without 
directly reducing the frequency or duration of obsessions or 
compulsions18 (Table 1). BDZs may also be used cautiously 
for short periods to counterbalance the early activation of 
SSRIs (Table 1).
Post-traumatic stress disorder
BZDs are among the most commonly prescribed psychotro-
pic medications in post-traumatic stress disorder (PTSD), 
despite the fact that most guidelines agree on the lack of 
evidence about their efficacy in this condition. Along with 
OCD, PTSD is one of the anxiety disorders mentioned in 
the earlier DSM-IV-TR (Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition Text Revision), and for 
which there is the lowest level of evidence supporting the 
use of BDZs.
Braun et al21 compared ten PTSD patients treated with 
alprazolam or placebo and then switched to the alternative 
treatment, demonstrating only minimal improvement for the 
active compound in reducing overall anxiety symptoms and no 
improvement in the core symptoms of PTSD. A subsequent 
randomized, single-blind, crossover study compared clon-
azepam and placebo in six patients with PTSD-related sleep 
disturbances,22 and found that clonazepam was largely ineffec-
tive in improving sleep disturbances, particularly nightmares.
The World Federation of Societies of Biological Psy-
chiatry (WFSBP) guidelines highlight the lack of evidence 
for use of BDZs in PTSD and contraindicate the early use 
of BDZs after exposure to trauma,23,24 consistent with the 
recommendations of the British Association for Psycho-
pharmacology (BAP).25
PTSD is unique amongst the psychiatric disorders for 
two main reasons: it usually has a clear point of onset and is 
characterized by a failure of the normal response to resolve.26 
Thus, secondary prevention is a core issue. However, BDZs 
were found to be ineffective in preventing PTSD in trauma 
survivors. Two studies comparing BDZs versus placebo for 
prevention of onset of PTSD in patients with acute stress 
disorder showed higher PTSD rates for subjects treated with 
BDZs.27,28 Therefore, BDZs may not only be ineffective, but 
may also be potentially damaging. In rats, for instance, alpra-
zolam given immediately after exposure to stress was found 
to interfere with the normal hypothalamic–pituitary–adrenal 
axis response to stress, thereby increasing vulnerability to 
subsequent stress.29
The revised Department of Veterans Affairs and 
Department of Defense clinical practice guidelines 
(2010)30 do not recommend the long-term use of BDZs 
because of a potential risk of dependence, which is high 
in PTSD and probably even higher in women,31–34 while 
the American Psychiatric Association (APA) guidelines35 
recommend individualized therapy to reduce anxiety or 
improve sleep.
In a recent RCT, Lee et al suggested the possibility of 
using lorazepam as a candidate anti-intrusion drug.36 Thus, 
comorbid anxiety disorder and specific PTSD symptoms may 
account for cautious use of BDZs in clinical practice, despite 
the guidelines not supporting it.35–37
Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1888
Dell’Osso et al
T
ab
le
 1
 G
ui
de
lin
es
 fo
r 
us
e 
of
 B
D
Z
s 
in
 o
bs
es
si
ve
–c
om
pu
ls
iv
e 
di
so
rd
er
, p
os
t-
tr
au
m
at
ic
 s
tr
es
s 
di
so
rd
er
, a
nx
ie
ty
, a
nd
 p
sy
ch
os
om
at
ic
 a
nd
 s
le
ep
 d
is
or
de
rs
D
is
or
de
r
B
A
P
 (
20
14
)
W
FS
B
P
 (
20
08
, 2
01
0,
 2
01
2)
A
P
A
 (
20
07
)
N
IC
E
 (
20
05
, 2
01
1)
C
lin
ic
al
 p
ra
ct
ic
e
O
bs
es
si
ve
–
co
m
pu
ls
iv
e 
di
so
rd
er
M
od
es
t 
do
se
s 
of
 B
D
Z
s 
m
ay
 b
e 
us
ed
 fo
r 
an
xi
et
y 
an
d 
di
st
re
ss
 
w
ith
ou
t 
re
du
ci
ng
 o
bs
es
si
on
s 
or
 
co
m
pu
ls
io
ns
BD
Z
s 
m
ay
 b
e 
us
ed
 c
au
tio
us
ly
 fo
r 
sh
or
t 
pe
ri
od
s 
to
 
co
un
te
rb
al
an
ce
 t
he
 
ea
rl
y 
ac
tiv
at
io
n 
of
 S
SR
Is
BD
Z
s 
ar
e 
w
id
el
y 
us
ed
 in
 c
lin
ic
al
 p
ra
ct
ic
e 
de
sp
it
e 
la
ck
 o
f e
vi
de
nc
e 
o
n 
th
ei
r 
ef
fic
ac
y.
 
C
lin
ic
ia
ns
 m
ay
 p
er
ce
iv
e 
BD
Z
s 
as
 u
se
fu
l 
ad
d-
on
 t
re
at
m
en
ts
 fo
r 
O
C
D
 p
at
ie
nt
s,
 a
t 
le
as
t 
at
 t
he
 b
eg
in
ni
ng
 o
f S
SR
I t
re
at
m
en
t
Po
st
-t
ra
um
at
ic
 
st
re
ss
 d
is
or
de
r
N
o
 e
ffi
ca
cy
 (
al
pr
az
o
la
m
 in
 a
cu
te
 
tr
ea
tm
en
t)
N
o
 e
ffi
ca
cy
 f
o
r 
PT
SD
La
ck
 o
f e
vi
de
nc
e.
 B
D
Z
s 
ar
e 
co
nt
ra
in
di
ca
te
d 
in
 t
he
 fi
rs
t 
fe
w
 
ho
ur
s 
af
te
r 
tr
au
m
a 
ex
po
su
re
B
D
Z
s 
ar
e 
no
t 
a 
fir
st
-l
in
e 
tr
ea
tm
en
t, 
bu
t m
ay
 b
e 
co
ns
id
er
ed
 
he
lp
fu
l o
n 
th
e 
ba
si
s 
of
 in
di
vi
du
al
 
ci
rc
um
st
an
ce
s,
 in
 o
rd
er
 t
o 
re
du
ce
 
an
xi
et
y 
or
 im
pr
ov
e 
sl
ee
p
BD
Z
s 
ar
e 
am
on
g 
th
e 
m
os
t 
co
m
m
on
ly
 
pr
es
cr
ib
ed
 p
sy
ch
ot
ro
pi
c 
m
ed
ic
at
io
ns
 in
 
PT
SD
, d
es
pi
te
 g
ui
de
lin
es
 d
is
co
ur
ag
in
g 
th
ei
r 
us
e
Pa
ni
c 
di
so
rd
er
A
lp
ra
zo
la
m
, c
lo
na
ze
pa
m
, d
ia
ze
pa
m
, 
an
d 
lo
ra
ze
pa
m
 a
re
 c
on
si
de
re
d 
am
on
g 
th
e 
ev
id
en
ce
-b
as
ed
 a
cu
te
 
th
er
ap
ie
s.
 T
he
 c
om
bi
na
tio
n 
fo
r 
a 
fe
w
 w
ee
ks
 o
f a
 B
D
Z
 w
ith
 a
 S
SR
I i
s 
re
co
m
m
en
de
d 
fo
r 
m
in
im
iz
in
g 
th
e 
si
de
 e
ffe
ct
s 
of
 t
he
 A
D
BD
Z
s 
co
m
bi
ne
d 
w
ith
 A
D
s 
in
 
th
e 
fir
st
 w
ee
ks
 o
f 
tr
ea
tm
en
t 
be
fo
re
 t
he
 o
ns
et
 o
f A
D
 e
ffe
ct
. 
BD
Z
s 
m
ay
 b
e 
us
ed
 in
 t
re
at
m
en
t 
re
si
st
an
t 
ca
se
s 
w
he
n 
th
e 
pa
tie
nt
 
do
es
 n
ot
 h
av
e 
a 
hi
st
or
y 
of
 
de
pe
nd
en
cy
BD
Z
s 
as
 a
dj
un
ct
iv
e 
tr
ea
tm
en
t 
to
 
A
D
s 
to
 im
pr
ov
e 
re
si
du
al
 a
nx
ie
ty
 
sy
m
pt
om
s
C
ur
re
nt
 c
lin
ic
al
 p
ra
ct
ic
e:
 B
D
Z
s 
as
 
ad
ju
nc
tiv
e 
tr
ea
tm
en
t 
to
 A
D
s.
D
es
ir
ab
le
 (
o
n 
th
e 
ba
si
s 
o
f 
th
e 
lit
er
at
ur
e)
 
cl
in
ic
al
 p
ra
ct
ic
e:
 B
D
Z
s
G
en
er
al
iz
ed
 
an
xi
et
y 
di
so
rd
er
A
lp
ra
zo
la
m
, d
ia
ze
pa
m
, a
nd
 
lo
ra
ze
pa
m
 a
re
 c
on
si
de
re
d 
am
on
g 
th
e 
ev
id
en
ce
-b
as
ed
 a
cu
te
 
tr
ea
tm
en
ts
, a
lth
ou
gh
 t
he
y 
ar
e 
no
t 
re
co
m
m
en
de
d 
as
 a
 fi
rs
t-
lin
e 
ch
o
ic
e
A
lp
ra
zo
la
m
 a
nd
 d
ia
ze
pa
m
 a
re
 
re
co
m
m
en
de
d.
 B
D
Z
s 
sh
ou
ld
 
on
ly
 b
e 
us
ed
 fo
r 
lo
ng
-t
er
m
 
tr
ea
tm
en
t 
w
he
n 
ot
he
r 
dr
ug
s 
or
 
C
BT
 h
av
e 
fa
ile
d
D
o 
no
t 
us
e 
BD
Z
s,
 
ex
ce
pt
 a
s 
a 
sh
or
t-
te
rm
 
m
ea
su
re
 d
ur
in
g 
cr
is
es
C
ur
re
nt
 c
lin
ic
al
 p
ra
ct
ic
e:
 B
D
Z
s 
as
 
ad
ju
nc
tiv
e 
tr
ea
tm
en
t 
to
 A
D
s
D
es
ir
ab
le
 (
o
n 
th
e 
ba
si
s 
o
f 
th
e 
lit
er
at
ur
e)
 
cl
in
ic
al
 p
ra
ct
ic
e:
 B
D
Z
s
So
ci
al
 a
nx
ie
ty
 
di
so
rd
er
C
lo
na
ze
pa
m
 a
nd
 b
ro
m
az
ep
am
 
ar
e 
lis
te
d 
as
 e
vi
de
nc
e-
ba
se
d 
tr
ea
tm
en
ts
, b
ut
 n
o
t 
as
 a
 fi
rs
t-
lin
e 
ch
oi
ce
C
lo
na
ze
pa
m
 is
 t
he
 o
nl
y 
BD
Z
 
lis
te
d 
am
on
g 
th
e 
ev
id
en
ce
-b
as
ed
 
th
er
ap
ie
s,
 w
ith
 li
m
ite
d 
ev
id
en
ce
.
BD
Z
s 
ca
n 
be
 c
om
bi
ne
d 
w
ith
 A
D
s 
in
 t
he
 fi
rs
t 
w
ee
ks
 o
f 
tr
ea
tm
en
t
Ps
yc
ho
so
m
at
ic
 
di
so
rd
er
s
La
ck
 o
f e
vi
de
nc
e
BD
Z
s 
ar
e 
no
t 
re
co
m
m
en
de
d 
(A
PA
 2
01
3)
BD
Z
s 
ar
e 
no
t 
us
ua
lly
 r
ec
om
m
en
de
d.
 
T
he
 m
os
t 
co
m
m
on
 t
re
at
m
en
ts
 a
re
 
“r
el
ax
in
g”
 t
ec
hn
iq
ue
s,
 C
BT
, S
N
R
Is
,  
an
d 
SS
R
Is
Sl
ee
p 
di
so
rd
er
s 
(i
ns
o
m
ni
a)
Z
 d
ru
gs
 a
nd
 s
ho
rt
-a
ct
in
g 
BD
Z
s 
ar
e 
ef
fic
ac
io
us
 fo
r 
sh
o
rt
-t
er
m
 in
so
m
ni
a 
(?
4 
w
ee
ks
)
BD
Z
s 
ar
e 
no
t 
re
co
m
m
en
de
d 
as
 
fir
st
-l
in
e 
tr
ea
tm
en
t.
 I
nt
er
ve
nt
io
ns
 
sh
ou
ld
 fo
cu
s 
on
 p
sy
ch
ol
og
ic
al
 
tr
ea
tm
en
ts
, i
nc
lu
di
ng
 C
BT
, s
le
ep
 
re
st
ri
ct
io
n 
an
d 
sl
ee
p 
hy
gi
en
e
A
bb
re
vi
at
io
ns
: B
Z
D
s,
 b
en
zo
di
az
ep
in
es
; B
A
P,
 B
ri
tis
h 
A
ss
oc
ia
tio
n 
fo
r 
Ps
yc
ho
ph
ar
m
ac
ol
og
y;
 W
FS
BP
, W
or
ld
 F
ed
er
at
io
n 
of
 S
oc
ie
tie
s 
of
 B
io
lo
gi
ca
l P
sy
ch
ia
tr
y;
 A
PA
, A
m
er
ic
an
 P
sy
ch
ia
tr
ic
 A
ss
oc
ia
tio
n;
 N
IC
E,
 N
at
io
na
l I
ns
tit
ut
e 
of
 C
lin
ic
al
 
Ex
ce
lle
nc
e;
 A
D
s,
 a
nt
id
ep
re
ss
an
ts
; P
T
SD
, p
os
t-
tr
au
m
at
ic
 s
tr
es
s 
di
so
rd
er
; B
D
Z
s,
 b
en
zo
di
az
ep
in
es
; S
SR
Is
, s
el
ec
tiv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
rs
; S
N
R
Is
, s
er
ot
on
in
–n
or
ep
in
ep
hr
in
e 
re
up
ta
ke
 in
hi
bi
to
rs
; C
BT
, c
og
ni
tiv
e-
be
ha
vi
or
al
 t
he
ra
py
.
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1889
Benzodiazepines today: heroes or villains?
Panic disorder and generalized anxiety disorder
Until the 1990s, experts recommending medication for panic 
disorder or generalized anxiety disorder (GAD) tended to 
choose a BDZ as first-line treatment.38 In the late 1990s, 
however, the recommendation for these disorders changed to 
an SSRI, and the majority of experts chose a combination of a 
BDZ and SSRI.38 Thereafter, there was a gradual decline in use 
of BDZs, with these agents drifting from first-line, to second-
line, to third-line treatment and being replaced by newer 
antidepressants. According to the most recent guidelines,25,39,40 
BDZs are still used as second- or third-line treatment.
Use of BDZs as monotherapy in the acute treatment 
of panic disorder has been extensively investigated in 
RCTs, with positive evidence for alprazolam, clonazepam, 
diazepam, and lorazepam in relieving the core symptoms 
of panic disorder. With regard to mid-term and long-term 
treatment, the current guidelines (Table 1) suggest use of 
BDZs as adjunctive treatment to antidepressants for improv-
ing residual anxiety symptoms and as monotherapy only 
in treatment-resistant cases. Nonetheless, Batelaan et al41 
reported that alprazolam and clonazepam were efficacious 
as maintenance treatment for panic disorder. More recently, 
Freire et al showed that clonazepam had a strong anti-panic 
effect, and that alprazolam, diazepam, and lorazepam had 
significant anti-panic effects.42 In addition, a recent meta-
analysis43 found that BDZs were more effective than tricyclic 
antidepressants in reducing the number of panic attacks and 
were significantly better tolerated than tricyclic antidepres-
sants, causing less side effects and discontinuation of therapy. 
With regard to comparison with newer antidepressants, 
Offidani et al43 found comparable efficacy for clonazepam 
and paroxetine, but better tolerability of clonazepam in 
patients with panic disorder.
Current guidelines (Table 1) suggest that BDZs (mainly 
alprazolam, diazepam, and lorazepam) are among the 
evidence-based acute treatments for GAD, although they are 
not recommended as the first-line choice. The suggestion is 
to use BDZs as adjunctive treatment to antidepressants (ie, 
SSRIs and serotonin-norepinephrine reuptake inhibitors). 
Unfortunately, BDZs and the newer antidepressants have 
been compared only in a minority of research studies, which 
do not seem to confirm that BDZs are less effective than 
the newer antidepressants. Berney et al44 found only one 
comparative study showing comparable efficacy between 
venlafaxine and diazepam in the treatment of GAD. Offidani 
et al43 showed no significant difference in response rates 
between diazepam, venlafaxine, and placebo. Moreover, 
they reported an improvement in somatic symptoms in GAD 
patients taking lorazepam versus those taking paroxetine or 
placebo. This finding is consistent with a recent report by 
Albert et al who found that BDZs were clearly effective in 
the treatment of somatic symptoms of GAD despite having 
a poor effect on its psychiatric component (worries, appre-
hensive expectations).45
In brief, the literature suggests that we need to reappraise 
the use of BDZs as first-line pharmacotherapy for panic dis-
order and GAD in the absence of a substance use disorder.46 
Some authors, for instance, have proposed choosing BDZs 
as first-line pharmacotherapy for panic disorder and GAD, 
and suggest that the choice between BDZs and antidepres-
sants for long-term treatment should be made on the basis 
of the patient’s preference and careful consideration of their 
individual circumstances.46
Social anxiety disorder
In double-blind studies, clonazepam (three studies) and bro-
mazepam (one study), but not alprazolam (one study), were 
shown to be superior to placebo in the acute treatment of social 
anxiety disorder (SAD).47 Consequently, clonazepam is the 
only BDZ listed among the evidence-based treatments for SAD 
by the WFSBP guidelines,23 despite the limited evidence from 
controlled studies (category of evidence B). In comparison 
with paroxetine and placebo, the combination of paroxetine 
and clonazepam did not show a more rapid response in SAD 
patients, but did provide a better overall outcome.48
For other anxiety disorders, the WFSBP guidelines sug-
gest that BDZs can be combined with antidepressants in the 
first weeks of treatment before the onset of antidepressant 
efficacy. The BAP guidelines list both clonazepam and bro-
mazepam as evidence-based treatments for SAD,25 although 
they suggest SSRIs as first-line treatment. BDZs may be used 
in treatment-resistant patients who have not responded to 
other approaches.25,49 The limited data on relapse prevention, 
potential withdrawal difficulties, and the restricted spectrum 
of action of BDZs in the generalized subtype of SAD limit 
their use in this condition.
In conclusion, there is good evidence for the efficacy of 
BDZs in the acute treatment of panic disorder, GAD, and 
(to a lesser degree) SAD, while there is poor evidence of 
efficacy in OCD. In PTSD, BDZs are considered ineffective, 
if not deleterious.
Psychosomatic disorders
Psychosomatic disorders are heterogeneous conditions for 
which there are a number of possible treatments.50 How-
ever, in this review, the focus is on psychosomatic diseases 
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that have been managed with BDZs. Most guidelines on 
the treatment of psychosomatic disorders do not explicitly 
recommend BDZs, but refer to generic “anxiolytic” or 
“relaxing” techniques.51 In psychosomatic disorders, first-
line treatments include duloxetine, milnacipran, tryciclic 
antidepressants and pregabalin,50,52 while BDZs (alprazolam 
and bromazepam) are not usually recommended as first-line 
treatment.
Antidepressants and anxiolytics are first-line therapy 
for the gastrointestinal manifestations of psychosomatic 
disorders, with psychotherapy, hypnosis, and relaxation 
techniques able to be used in the event of a poor response.53 
A combination of anxiolytic treatment and cognitive-behavioral 
therapy has been reported to be useful in patients with chronic 
gastritis.51
Sleep disorders
Sleep disorders are common, with chronic insomnia occur-
ring in about 10% of the general population and in about 
20% of the elderly.54 The treatment of sleep disorders, and 
insomnia in particular, is complex, and depends on numer-
ous patient-related factors, including age, likely duration 
of treatment, and psychiatric and medical comorbidity.55,56 
BDZs are frequently used to treat sleep disorders.57 Although 
guidelines for the treatment of insomnia emphasize that 
BDZs should only be used in the short term (not exceeding 
4–6 weeks) and advocate the use of psychological treatments 
as first-line therapy,58,59 their use beyond the licensed dura-
tion is widespread.8,9
However, BDZs and related BDZ receptor agonists are 
the most effective pharmacological treatment for insomnia 
to date.60 Rapid onset of efficacy and safety issues make it 
difficult to even contemplate forsaking the use of BDZs in 
clinical practice. Considering that the acute treatment of 
chronic insomnia often leads deliberately or inadvertently to 
long-term use, short (eg, zolpidem, triazolam) and medium 
(eg, lorazepam) half-life compounds are preferable, and are 
also preferred given their rapid absorption. Of note is that, 
until recently, BDZs were only available as immediate-
release formulations. Therefore, when a longer duration of 
action was required, agents with a longer half-life (eg, diaz-
epam, clonazepam) or increased doses were selected, with an 
increased risk of next-day residual effects. Modified-release 
formulations, such as that for alprazolam, offer a more suit-
able pharmacokinetic profile.61
With respect to use of BDZs in the elderly, the prescrib-
ing guidelines continue to emphasize short-term and low-
dose use of medications with a short half-life along with 
non-pharmacological treatments, including appropriate sleep 
hygiene and treatment of other medical or psychiatric causes 
of disturbed sleep.62
When used to treat insomnia, BDZs initially lead to 
prolonged total sleep time. Acute and short-term use is 
also associated with a reduction in nocturnal wake time 
and subjective improvements in quality and depth of sleep, 
along with improved sleep continuity, as reported by poly-
somnographic studies.63 With respect to sleep microarchi-
tecture, BDZs are associated with a significant decrease in 
electroencephalographic arousals, as well as a reduction 
of slow frequencies and an increase in fast frequencies 
on the electroencephalogram.64 Further, BDZs reduce the 
instability of non-rapid eye movement sleep and protect 
against noise-induced perturbation.65,66 However, chronic 
BDZ use in sleep-disordered patients is associated with a 
peculiar pattern of sleep modification involving all levels of 
sleep organization.67 Poor subjective sleep quality, a marked 
increase in nocturnal awakenings, and gross disruption of 
the non-rapid/rapid eye movement sleep cycle have been 
reported.67
In light of the efficacy, tolerability, and patient accept-
ability of BDZs, the risk–benefit ratio is positive in most 
sleep-disordered patients in the short term but is unestab-
lished beyond that time. In particular, the controversy about 
whether the short-term benefits outweigh the possible risk 
of dependence has never been resolved.7 The advent of other 
effective and often safer agents for the treatment of insomnia 
is changing the parameters of this debate. “Z” drugs (ie, 
zolpidem, zopiclone, eszopiclone, zaleplon) are also posi-
tive allosteric modulators of the gamma aminobutyric acid 
(GABA)-A receptor and have a safety and efficacy profile 
similar to that of the BZDs but a low abuse potential.8
Guidelines for the use of BDZ in sleep disorders should 
be targeted at the main prescribers (ie, psychiatrists, pri-
mary care physicians) and should include information on 
the evidence for alternative forms of treatment (ie, non-
pharmacological alternatives for insomnia, such as cognitive-
behavioral therapy).8 Findings for the use of BDZs in OCD, 
PTSD, anxiety, and psychosomatic and sleep disorders are 
summarized in Table 1.
Use of BDZs in primary psychoses 
and depressive disorders
Schizophrenia and treatment-resistant schizophrenia
The use of BDZs in schizophrenia is controversial. In fact, 
even though these compounds have no specific indication for 
schizophrenia, recent guidelines and metanalyses68–70 mention 
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their use in association with antipsychotics for their sedative 
and anxiolytic effects.71–74 In particular, the Schizophrenia 
Patient Outcomes Research Team guidelines75 recommend 
the use of BDZs, alone or in combination with antipsychot-
ics, in the pharmacological treatment of acute agitation in 
people with schizophrenia. However, the current level of 
evidence supporting their use for the management of anxiety 
and depressive symptoms in patients with schizophrenia is 
limited, although APA guidelines76 suggest that BDZs may be 
helpful for managing anxiety during the stable phase of treat-
ment and for acute agitation. However, use of BDZs in this 
group of patients is often contraindicated due to side effects, 
such as sedation, ataxia, cognitive impairment, behavioral 
disinhibition, re-exacerbation of psychotic symptoms, and 
seizures.76
Despite the paucity of evidence-based data on use of 
BDZs in patients with treatment-resistant schizophrenia, 
BDZs may be prescribed in this population depending on 
the severity of psychotic symptoms, the side effects of 
high doses of antipsychotics, and refractory symptoms not 
responding to adequate trials of antipsychotics.77 Nonethe-
less, a recent systematic review has questioned the efficacy 
of augmentative BDZs to antipsychotics in the treatment of 
patients with schizophrenia,68 recommending their use be 
limited in clinical practice.
A recent Cochrane systematic review of the efficacy of 
BDZs in psychosis-induced aggression or agitation con-
cluded that adding BDZs to other drugs does not appear to 
be clearly advantageous and increases the risk of unnecessary 
adverse effects.78 Further, a recent meta-analysis69 of 16 RCTs 
(for a total of 1,045 participants) investigating the efficacy 
of BDZ augmentation to antipsychotics in the treatment of 
schizophrenia found no evidence for use of this strategy.
Use of BDZs in patients with schizophrenia has been 
associated with a substantial increase in the mortality hazard 
ratio, both for suicidal and non-suicidal deaths. Notably, 
a similar increase in the mortality hazard ratio has not been 
found in patients with schizophrenia treated with two or 
more concomitant antipsychotics or with an antidepressant-
antipsychotic combination.79 In one study, use of BDZs 
with a long half-life increased the risk of natural death in 
patients with schizophrenia treated using antipsychotics.80 
According to these observations, use of BDZs in patients 
with schizophrenia, and particularly those with treatment-
resistant schizophrenia, should be discouraged when directed 
at augmenting antipsychotic efficacy, while their use might 
be cautiously considered when non-psychotic symptoms, 
such as anxiety or sleep disturbances, are present.
Major depressive disorder and treatment-resistant 
depression
Most comparative studies of classical (non-triazolo) BDZs 
in major depressive disorder (MDD) show that these agents 
do not alleviate the core symptoms of depression, although 
they do improve sleep and anxiety.81 Classical BDZs show 
some favorable effects in minor depression, but their efficacy 
could be different in patients suffering from comorbid anxiety 
disorders. Classical BDZs, alprazolam in particular, have 
been found to be effective in mild and moderate depression, 
although generally inferior to tricyclic antidepressants.81 
Therefore, although BDZs are not recommended as mono-
therapy in the treatment of depressive disorders, depressed 
patients treated in mental health settings commonly receive 
long-term treatment with BDZs in combination with 
antidepressants.82
A number of RCTs have examined the efficacy of adjunc-
tive BDZs for the treatment of MDD. At low doses and for 
short-term use, diazepam, chlordiazepoxide, clonazepam, 
lormetazepam, and alprazolam have demonstrated efficacy 
in patients with MDD.83,84 A meta-analysis of all combina-
tion therapy trials85 showed that patients on combination 
therapy were more likely to respond than those receiv-
ing antidepressants only at 1, 2, and 4 weeks; moreover, 
patients on combination therapy were less likely to drop out 
than those receiving antidepressants only. However, these 
differences were no longer significant at 6 and 8 weeks. 
Indeed, the beneficial effects of antidepressants appear only 
after a few weeks of treatment, so BDZs may be helpful for 
the initial treatment of symptoms such as restlessness and 
sleeplessness.82 BDZs may also improve adherence to treat-
ment by reducing some of the side effects of antidepressants, 
especially at the start of treatment.85
BDZs may be particularly indicated in patients whose 
depressive symptoms are accompanied by anxiety. Indeed, 
in up to 50% of patients, depressive disorders are associ-
ated with anxiety disorders or symptoms.86 Although many 
antidepressants are effective for both depressive and anxiety 
symptoms, studies in patients with mixed anxious-depressive 
features show that combined treatment is more useful for 
rapid control of restlessness and insomnia.86,87
Use of BDZs in combination with antidepressants is usu-
ally considered safe. However, BDZs may be dangerous in 
certain situations, eg, when they are prescribed for depressed 
patients who abuse alcohol or for the elderly,85 or when they 
are used for long periods. There are several potential risks 
associated with long-term use of BDZs in patients with MDD, 
owing to the relatively high potential for abuse, tolerance, 
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and side effects, such as falls, cognitive impairment, and 
paradoxical activation.88–91
Another area of potential clinical usefulness for BDZs is 
treatment-resistant depression, generally defined as failure 
to achieve remission after at least two trials of antidepres-
sant treatment of adequate duration and dose.92 Despite an 
increasing variety of choice, BDZs are widely used in clinical 
practice to improve residual symptoms of depression and/
or anxiety, but their use as add-on treatments in resistant or 
prolonged depression is only supported by some case reports 
and open studies.93 In particular, recent evidence has been 
provided by the STAR*D (Sequenced Treatment Alterna-
tives to Relieve Depression) study,94,95 in which researchers 
found that patients affected by anxious depression have a 
slow response rate to antidepressive treatment.96,97 Therefore, 
higher rates of anxiolitics and of sedative hypnotics are used in 
this group of patients in order to to manage comorbid anxiety 
disorders in patients who do not respond to antidepressants.98 
Although BDZs can provide rapid symptom relief at the start 
of antidepressant therapy along with improved adherence to 
antidepressants,85,99 their use is a significant predictor of treat-
ment resistance in older adults with depression.100 However, 
this finding should be interpreted with caution, since BDZs 
are probably used to treat anxiety and/or sleep disturbances 
in such patients. Thus, poor recovery and treatment resistance 
in these patients may be due to comorbid illness. An alter-
native explanation is that use of BDZs may indicate greater 
severity of depression necessitating polypharmacy. A more 
detailed pharmacological study may elucidate the relation-
ship between the intensity of antidepressant treatment and 
outcome with regard to depression.100
The Canadian Network for Mood and Anxiety Treatments101 
and the APA guidelines for the treatment of MDD102 advise limit-
ing the use of BDZs in patients with primary MDD to those with 
pronounced anxiety or persistent insomnia not adequately relieved 
by SSRIs or serotonin-norepinephrine reuptake inhibitors.
Bipolar disorder
BDZs are widely prescribed for patients with bipolar 
disorder,103 usually for a short period of time (up to 2 weeks) 
and as an adjunct to mood stabilizers. The rationale for their 
use is to help gain rapid control of certain symptoms of 
mania (such as restlessness, agitation, and insomnia) until 
mood-stabilizing drugs start showing their effect.104 Despite 
their use in clinical practice, the evidence-based data are 
conflicting, with some studies suggesting potential efficacy of 
BDZs for treating anxiety symptoms105 and others showing a 
greater risk for recurrence of mood episodes.106 The recently 
published CHOICE (Clinical and Health Outcomes Initiative 
in Comparative Effectiveness) trial showed that adjunctive 
BDZs do not significantly affect the clinical outcome in 
patients treated with lithium or quetiapine.107
Treatment recommendations for the use of BDZs in 
bipolar disorder vary across the different international 
guidelines.108,109 No specific recommendations are given 
for acute bipolar depression, while some suggestions are 
available for acute mania (Table 2). Adjunctive treatment 
with clonazepam or lorazepam for reducing agitation, 
anxiety, and promoting sleep in the short-term is recom-
mended by the BAP110 and WFSBP guidelines.111 The 
Canadian Network for Mood and Anxiety Treatments and 
the International Society for Bipolar Disorders guidelines112 
advocate the use of adjunctive BDZs in patients who refuse 
oral medications for agitation, but not as monotherapy. 
The APA guidelines113 suggest their short-term adjunctive 
use in manic/mixed episodes, agitation, and catatonia. 
The National Institute for Health and Clinical Excellence 
(NICE) guidelines114 recommend considering addition of 
short-term BDZs (eg, lorazepam) for behavioral distur-
bances or agitation. If the behavioral disturbance is severe, 
they suggest an oral medication first, such as lorazepam, or a 
combination of a BDZ and an antipsychotic. Intramuscular 
lorazepam is also recommended if rapid tranquillization 
is needed.
Malhi et al115 (National Health and Medical Research 
Council) in their clinical practice recommendations for 
bipolar disorder suggest short-term use of a BDZ (lorazepam) 
for acute behavioral disturbances. However, if intramuscular 
administration is necessary, an injectable atypical antipsy-
chotic or a combination of an injectable typical antipsychotic 
and a BDZ are suggested. Moreover, the BAP guidelines110 
recommend the use of BDZs in the long-term treatment of 
bipolar disorders in case of acute stressors, early relapse 
symptoms (especially insomnia), or anxiety. The NICE 
guidelines suggest long-term use of BDZs in patients with a 
significant comorbid anxiety disorder.114
In conclusion, the treatment of bipolar disorder is com-
plex and use of BDZs is controversial, so although the current 
treatment guidelines are useful for clinicians, they do not 
accurately reflect everyday clinical practice.
Antipsychotic-induced movement disorders
BDZs have been widely used in the past for the treatment 
of antipsychotic-induced movement disorders, such as acute 
dystonia, akathisia, neuroleptic-induced malignant syndrome 
and tardive dyskinesia.116–121
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1893
Benzodiazepines today: heroes or villains?
T
ab
le
 2
 G
ui
de
lin
es
 fo
r 
us
e 
of
 B
D
Z
s 
in
 p
ri
m
ar
y 
ps
yc
ho
se
s 
an
d 
de
pr
es
si
ve
 d
is
or
de
rs
D
is
or
de
r
B
A
P
 (
20
09
)
C
A
N
M
A
T
 (
20
13
)
P
O
R
T
 (
20
09
)
A
P
A
 (
20
04
)
N
IC
E
 (
20
14
)
W
FS
B
P
 (
20
12
)
C
lin
ic
al
 p
ra
ct
ic
e
Sc
hi
zo
ph
re
ni
a 
an
d 
tr
ea
tm
en
t-
re
si
st
an
t 
sc
hi
zo
ph
re
ni
a
BD
Z
s,
 a
lo
ne
 o
r 
in
 
co
m
bi
na
tio
n 
w
ith
 
an
tip
sy
ch
ot
ic
s,
 
fo
r 
tr
ea
tm
en
t 
of
 
ac
ut
e 
ag
ita
tio
n
BD
Z
s 
he
lp
fu
l f
or
 
m
an
ag
in
g 
an
xi
et
y 
du
ri
ng
 
th
e 
st
ab
le
 p
ha
se
 o
f 
tr
ea
tm
en
t 
an
d 
fo
r 
ac
ut
e 
ag
ita
tio
n
BD
Z
s 
ar
e 
fr
eq
ue
nt
ly
 u
se
d 
in
 a
ss
oc
ia
tio
n 
w
ith
 A
Ps
.
BD
Z
 u
se
 s
ho
ul
d 
be
 
di
sc
ou
ra
ge
d 
w
he
n 
di
re
ct
ed
 
at
 a
ug
m
en
ti
ng
 A
P 
ef
fic
ac
y.
 
BD
Z
s 
co
ul
d 
be
 c
on
si
de
re
d 
fo
r 
an
xi
et
y 
or
 s
le
ep
 
co
m
or
bi
d 
di
st
ur
ba
nc
es
D
ep
re
ss
io
n 
an
d 
tr
ea
tm
en
t-
re
si
st
an
t 
de
pr
es
si
on
BD
Z
s 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 p
ro
no
un
ce
d 
an
xi
et
y/
in
so
m
ni
a 
no
t 
re
sp
on
di
ng
 
to
 S
SR
I o
r 
SN
R
I
BD
Z
s 
us
ed
 in
 p
at
ie
nt
s 
w
ith
 p
ro
no
un
ce
d 
an
xi
et
y/
in
so
m
ni
a 
no
t 
re
sp
on
di
ng
 t
o 
SS
R
I o
r 
SN
R
I
Bi
po
la
r 
di
so
rd
er
s
A
dj
un
ct
iv
e 
cl
on
az
ep
am
 o
r 
lo
ra
ze
pa
m
 fo
r 
ag
ita
te
d 
pa
tie
nt
s 
or
 
sl
ee
p 
di
st
ur
ba
nc
es
 
in
 t
he
 s
ho
rt
 t
er
m
BD
Z
s 
no
t 
in
 m
on
ot
he
ra
py
.
U
se
 o
f B
D
Z
s 
in
 p
at
ie
nt
s 
re
fu
si
ng
 o
ra
l m
ed
ic
at
io
ns
 
as
 a
dj
un
ct
s 
to
 s
ed
at
e 
ac
ut
el
y 
ag
ita
te
d 
pa
tie
nt
s
Sh
or
t-
te
rm
 a
dj
un
ct
iv
e 
in
 m
an
ic
 o
r 
m
ix
ed
 
ep
is
od
es
, i
n 
se
ve
re
ly
 
ill
 o
r 
ag
ita
te
d 
pa
tie
nt
s,
 
an
d 
ca
ta
to
ni
c 
sy
m
pt
om
s 
(c
lo
na
ze
pa
m
 a
nd
 
lo
ra
ze
pa
m
 a
lo
ne
 a
nd
 
in
 c
om
bi
na
tio
n 
w
ith
 
lit
hi
um
)*
Sh
or
t-
te
rm
 B
D
Z
s 
fo
r 
be
ha
vi
or
al
 d
is
tu
rb
an
ce
s 
or
 a
gi
ta
tio
n.
Lo
ng
-t
er
m
 u
se
 fo
r 
pa
tie
nt
s 
w
ith
 c
om
or
bi
d 
an
xi
et
y 
di
so
rd
er
s
C
lo
na
ze
pa
m
 a
nd
 
lo
ra
ze
pa
m
 a
s 
ad
d-
on
 tr
ea
tm
en
t 
to
 p
ri
m
ar
y 
m
oo
d 
st
ab
ili
ze
rs
BD
Z
s 
ar
e 
w
id
el
y 
pr
es
cr
ib
ed
, u
su
al
ly
 fo
r 
a 
sh
or
t 
tim
e,
 a
s 
ad
ju
nc
tiv
e 
tr
ea
tm
en
t 
to
 m
oo
d-
st
ab
ili
zi
ng
 d
ru
gs
N
ot
e:
 *
R
ef
er
s 
to
 A
PA
 G
ui
de
lin
es
 2
00
2 
Ed
iti
on
 fo
r 
m
an
ag
em
en
t 
of
 b
ip
ol
ar
 d
is
or
de
rs
. 
A
bb
re
vi
at
io
ns
: B
A
P,
 B
ri
tis
h 
A
ss
oc
ia
tio
n 
fo
r P
sy
ch
op
ha
rm
ac
ol
og
y;
 W
FS
BP
, W
or
ld
 F
ed
er
at
io
n 
of
 S
oc
ie
tie
s o
f B
io
lo
gi
ca
l P
sy
ch
ia
tr
y;
 A
PA
, A
m
er
ic
an
 P
sy
ch
ia
tr
ic
 A
ss
oc
ia
tio
n;
 N
IC
E,
 N
at
io
na
l I
ns
tit
ut
e 
of
 C
lin
ic
al
 E
xc
el
le
nc
e;
 C
A
N
M
A
T
, C
an
ad
ia
n 
N
et
w
or
k 
fo
r 
M
oo
d 
an
d 
A
nx
ie
ty
 T
re
at
m
en
ts
; P
O
R
T
, S
ch
iz
op
hr
en
ia
 P
at
ie
nt
 O
ut
co
m
es
 R
es
ea
rc
h 
T
ea
m
; A
P,
 a
nt
ip
sy
ch
ot
ic
; B
D
Z
s,
 b
en
zo
di
az
ep
in
es
; S
SR
Is
, s
el
ec
tiv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
rs
; S
N
R
Is
, s
er
ot
on
in
–n
or
ep
in
ep
hr
in
e 
re
up
ta
ke
 
in
hi
bi
to
rs
.
Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1894
Dell’Osso et al
Two systematic Cochrane reviews have specifically 
addressed the use of BDZs in antipsychotic drug-induced 
movement disorders. The first review122 assessed the effects 
of BDZs versus placebo in people with akathisia, with only 
two small trials identified. By the second week of treatment, 
a reduction in symptoms was found for patients receiving 
clonazepam when compared with those on placebo. No sig-
nificant difference was detected for adverse events or need 
for anticholinergic medication. Despite stressing the lack of 
large controlled trials in the field, the authors concluded that 
the use of BDZs may reduce the symptoms of antipsychotic-
induced acute akathisia in the short term.
A subsequent review123 sought to determine the effects of 
BDZs on neuroleptic-induced tardive dyskinesia in people 
with schizophrenia or other chronic mental illness. The 
selection criteria allowed only three trials to be included in 
the analysis. The use of BDZs as adjunctive treatment did 
not produce any clear change in a series of medium-term 
outcomes regarding tardive dyskinesia. One trial found bet-
ter final abnormal movement scores for patients receiving 
adjunctive BDZs. The reviewers concluded that only one 
small study reported preliminary positive evidence in favor 
of BDZs in the treatment of neuroleptic-induced tardive 
dyskinesia. However, due to the inconclusive results from 
other studies, the use of BZDs for this purpose in clinical 
practice remains experimental.
Treatment of neuroleptic-induced acute and tardive dys-
tonia with BDZs has not been the subject of any systematic 
reviews or meta-analyses, with only a few case reports pub-
lished supporting their use, which was mostly to augment 
atypical antipsychotics.124,125 The putative benefit of BDZs 
in the treatment of neuroleptic malignant syndrome has not 
been assessed in comparison with other compounds, and is 
mostly based on a series of case reports.119,126–129 Findings 
for the use of BDZs in primary psychoses and depressive 
disorders are summarized in Table 2.
Use of BDZs in impulse control, and 
personality, eating, and addictive disorders
Impulse control disorders
DSM-IV-TR impulse control disorders (ICDs) not elsewhere 
classified have been included by the DSM-5 (Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition) 
within disruptive, impulse control, and conduct disorders, 
with previous pathological gambling and trichotillomania 
being included in other chapters (ie, substance-related and 
addictive disorders and obsessive–compulsive and related 
disorders).130,131
Given that treatment guidelines for traditional ICDs are 
lacking,132 and that conditions grouped in the new DSM-5 
chapter are arranged developmentally, including conditions 
like oppositional defiant disorder and conduct disorder with 
childhood and adolescent onset, it is difficult to extrapolate 
indications and recommendations from the available litera-
ture about BDZs in the field. Therefore, clinical indications 
regarding use of BDZs in these disorders may be mostly 
obtained from the treatment of aggressive dyscontrol,133,134 
which dimensionally characterizes some ICDs (eg, inter-
mittent explosive disorder) as well as other mental disor-
ders. If, on the one hand BDZs are often used effectively 
in aggressive patients, with the possibility of being given 
intramuscularly to achieve a rapid onset of action134 stud-
ies describing paradoxical aggressive reactions have been 
reported as well.135 A recent review on the topic, examining 
46 studies, could not conduct a meta-analysis due to the 
heterogeneity of study design and BDZ class and doses.136 
However, most rigorous studies reported an association 
between use of BDZs and subsequent aggressive behavior.136 
Of note, Albrecht et al indicated that higher doses are more 
risky following repeated administration, and trait levels of 
anxiety and hostility may indicate a vulnerability to BDZ-
related aggression.136
Borderline personality disorder
Clinical and experimental data on the role of BDZs in the 
treatment of borderline personality disorder (BPD) are scarce 
and inadequate. Although preliminary reports indicated 
the potential efficacy of alprazolam and clonazepam in the 
management of impulsivity and anxiety,137,138 a subsequent 
controlled study suggested that administration of alprazolam 
might result in disinhibition and dyscontrol.139 Several per-
sonality traits, including BPD traits, particularly combined 
with alcohol use, have been correlated with an increased risk 
of aggressive behavior following BDZ use.4,136 The APA 
guidelines suggest use of BDZs, particularly clonazepam, 
in the treatment of “affect dysregulation” in the presence 
of anxiety symptoms that either fail to respond or respond 
only partially to antidepressants.140 Concurrently, caution is 
recommended due to the high risk of abuse, tolerance, and 
toxicity of BZDs, and the use of other sedative compounds 
is advocated. The 2009 NICE guidelines141 support the use 
of BDZs as a short-term, second-line therapy in conditions 
of “crisis” and for the treatment of severe insomnia requiring 
a rapid-acting drug. However, in spite of the scarce and con-
flicting findings of the available studies, as well as the poten-
tial risks,142–144 BDZs are still widely used in BPD patients. 
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The frequent use of these drugs may be linked to their rapid 
onset of action, the wide range of clinical applications, the 
favorable tolerability/efficacy ratio, the ease of prescription 
compared with other drugs, and the need for fast-acting 
therapeutic options due to the unstable clinical picture.
Eating disorders
The most recent guidelines on the treatment of eating dis-
orders do not specifically consider the use of BDZs.145–148 
However, BDZs are sometimes used in subjects with eat-
ing disorders, mostly when a comorbid anxiety disorder is 
present,149 or to treat anxiety related to food/body issues, 
severe insomnia, or excessive physical exercise, although no 
controlled evidence is available to guide such choices.150
Any off-label use of BDZs in a patient with an eating 
disorder should be carefully evaluated and individually 
planned, and in light of the specific risks for addiction and 
drug abuse,9,151 particularly when marked addictive person-
ality characteristics are present.152 Further, because of their 
sedative effects and their tendency to increase the palatability 
of food and its ingestion, there is a potential risk for weight 
increase on BDZs.153
A special case for the use of BDZs is the night eating 
syndrome. Originally described by Stunkard et al154 this dis-
order is characterized by insomnia and awakenings associated 
with substantial night eating. A literature review155 revealed 
that night eating syndrome is consistently related to mood 
and anxiety disorders, and the few available studies of its 
pharmacological treatment have mostly focused on SSRIs. 
Therefore, blurred indications on the potential benefits of 
some BDZs (oxazepam, clonazepam) for night eating syn-
drome are only anecdotally provided.156,157
To conclude, no clear indications about whether, when, 
or how to use BDZs in patients with eating disorders are 
available. Further investigation is needed to explore the full 
potential of the use of BDZs in eating disorders.
Dual diagnosis
People with severe mental illness have high rates of comorbid 
substance use, ie, “dual diagnosis.”158,159 Along with illicit 
drugs, they often abuse alcohol and/or BDZs,160 with higher 
dependence risk.161 Dose, route of administration, coadmin-
istration with other drugs, context of use, and expectations 
are associated with substance dependence.162 However, the 
research evidence based on BDZs in patients with co-occur-
ring substance use disorder is limited. In general, BDZ use is 
higher among people with bipolar disorder and co-occurring 
substance use disorder, with about half taking BDZs at least 
at one longitudinal assessment point, having higher scores of 
overall and affective symptoms and lower scores for quality 
of life, and a greater proportion (15% versus 6%) progress-
ing to BDZ abuse.163 People with comorbid substance use 
disorder and major depression seem more likely to use fast-
acting/high-potency BDZs, and those with comorbid bipolar 
disorder receive higher diazepam-equivalent doses.164
A Taiwanese study showed that patients with severe 
mental illness and higher BDZ doses were more likely to 
have co-occurring alcohol abuse/dependence.165 In France, 
problematic BDZ users showed more severe depression and 
anxiety, with poor quality of life.166 Finally, a recent Italian 
study found that women with a dual diagnosis were more 
likely to become BDZ-dependent.167
Specific guidelines regarding the assessment and treat-
ment of BDZ misuse in people with dual diagnosis are scant. 
The only specific recommendations come from the NICE168 
and BAP169 guidelines and are shown in Table 3. In conclu-
sion, caution should be used in prescribing BDZs to people 
with severe mental illness and co-occurring substance use 
disorder.
Novel psychoactive substance abuse
Over the last decade, beyond “classical” substances of abuse, 
novel psychoactive substances (NPS) have become a new 
health issue of growing importance.170 In order to obtain spe-
cific rewarding effects and/or to “calm down” the psychoto-
mimetic symptoms induced by NPS, BDZs are often misused 
by this group of patients.170,171 BDZs with high potency and/or 
a short half-life are usually preferred. Cases of misuse have 
been reported in Russia for flunitrazepam, clonazepam, and 
phenazepam,172–174 which are all nitro-BDZs. The phenomenon 
of “date rape” or robbery has been connected to BDZ consump-
tion or unaware administration, with dissociative experiences, 
derealization, and anterograde amnesia being common.175,176
Polysubstance abuse is another common finding in sub-
jects using NPS; in particular, BDZs are frequently associated 
with synthetic cannabinoids, phenethylamines, mephedrone, 
and ketamine.177 Their pharmacodynamic and pharmacoki-
netic interactions remain mostly unknown, but are likely to 
be dangerous and potentially fatal.178
The therapeutic use of BDZs in subjects with specific 
addiction potential is controversial and may pose serious 
risks, although anxiety, panic attacks, phobias, and insom-
nia represent typical symptoms of acute and chronic NPS 
consumption. BDZ administration in cases of acute NPS 
intoxication may be required and have been reported to 
be beneficial,179 although the risks of excessive sedation, 
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memory deficits, and respiratory depression need to be 
monitored. BDZs with low potency, a long half-life, and 
without cytochrome metabolism are preferred. Oxazepam, 
chlordiazepoxide, alprazolam, and lorazepam have been 
used in subjects with multiple substance abuse, including 
NPS.180,181 However, given the relevant addiction potential, 
other pharmacological strategies, such as gabapentin, tra-
zodone, and pregabalin should be considered.182 Findings for 
the use of BDZs in impulse control, personality, eating, and 
addictive disorders are summarized in Table 3.
Use of BDZs in special patient 
populations
Cancer patients
BDZs have been used for a long time in the treatment of 
many psychological symptoms, including anxiety, insom-
nia, and stress-related symptoms, in cancer patients, and a 
steady increase in their prescription has been observed in 
recent years.183
Although BDZs usually have a favorable safety profile, 
their therapeutic/toxic ratio could be smaller than with 
other drugs in cancer patients.184 Potential BDZ-associated 
medical emergencies include hypotension, bradycardia, 
decreased respiratory drives, and respiratory arrest. These 
risks are increased when BDZs are used with other central 
nervous system depressants (eg, opioids, anti-hypertensive 
agents, alcohol).185 Especially in the critically ill and cog-
nitively impaired, as well as in elderly cancer patients, 
BDZs can impair memory, worsen disorientation, generate 
paradoxical effects (eg, anxiety, irritability, behavioral 
disinhibition), and exacerbate delirium.186 BDZs may also 
produce sedation and dizziness, contributing to the fatigue 
and weakness related to cancer and its specific treatments.184 
Moreover, BDZs may antagonize the analgesia induced 
by morphine and other opioids by increasing the action of 
GABA at the level of GABA-A receptors in the circuits of 
pain modulation.187
Considering the potential side effects and interactions, 
shorter-acting BDZs, such as lorazepam and oxazepam for 
anxiety, or temazepam for insomnia, should be preferred, 
and at low dosages for limited periods.188 Given their rapid 
effects and effectiveness, BDZs can be useful in the treatment 
of anxiety symptoms in acute conditions and in terminally ill 
cancer patients.189,190 They are also commonly prescribed in 
specific clinical situations; in combination with antiemetics 
and behavioral techniques, lorazepam and alprazolam were 
found to be effective for chemotherapy-related anticipatory 
and acute nausea/vomiting.191,192 Midazolam, a BDZ with 
high sedative and amnesic effects, is often administered 
in combination with anesthetic drugs to cancer patients 
when they are undergoing invasive procedures (endoscopy, 
biopsy),193 as well as to treat symptoms such as extreme 
anxiety, pain, dyspnea, restlessness, and agitated delirium 
within palliative sedation protocols.194 Research is needed 
to define scientific evidence regarding the use of BDZs in 
oncology, especially in palliative care.
Migrants
Migration can be to another country or within the same coun-
try. Migrants may decide to leave their own country in order 
to achieve personal development, or they may be pushed out 
of their country due to poverty, terrorism, or religion. Migra-
tion itself is the actual stage of moving across boundaries, and 
the subsequent period, called post-migration, is also important 
in terms of the individual adjusting and settling down. The 
term “migrants” therefore includes both persons who have 
migrated and settled and those who are still unsettled/migrat-
ing, since they both have similar risk of developing mental 
health problems.195 People with a history of migration have 
many risk factors for misuse of BDZs, so these agents need 
to be prescribed cautiously in this heterogeneous group.
Issues often associated with migrant status include a his-
tory of trauma or stressful life events, social exclusion/social 
fragility,196–198 difficulty in accessing psychiatric care,199–202 
and substance use,162 and all are also important predictors of 
misuse of BDZs. Clinicians should assess for the presence 
of these factors in people with a history of migration, and 
be particularly cautious when prescribing BDZs for these 
patients. Further studies are needed to better clarify which 
BDZs are more appropriate in migrant patients.
Suicidal patients
Suicide was recently highlighted by the World Health 
Organization as a major health issue worldwide.203 Regard-
less of a specific psychiatric diagnosis or stressful life events, 
suicidal individuals often present symptoms of anxiety and 
agitation that require prompt therapeutic action. However, 
very few studies exist on the effects of anxiolytics on suicidal 
behavior. Back in 1990, Fawcett et al204 reported that modifi-
able risk factors for suicide included severe psychic anxiety, 
agitation, panic attacks, and severe insomnia, and that these 
symptoms were associated with clinical depression.
There is limited evidence on the role of BDZs in either 
preventing or increasing suicide risk. Shih et al205 recently 
reported that patients taking higher average cumulative 
BDZ doses were at greater risk of deliberate self-poisoning. 
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According to Neutel and Patten,206 the association between 
BDZ use and attempted suicide was particularly high. 
A meta-analysis of controlled clinical trials of treatments for 
several different anxiety disorders found little difference in 
rates of completed and attempted suicide in patients treated 
with anxiolytic medications compared with placebo.207 
According to one report,208 longer-acting agents are pref-
erable to shorter-acting ones to prevent rebound anxiety. 
Disinhibition precipitated by BDZ therapy139 (although found 
only occasionally) and BDZ discontinuation209,210 may be 
associated with an increased suicide risk.
Given the fact that anxiety and agitation are modifiable 
risk factors, it seems wise to use BDZs (often in combina-
tion with other agents) in suicide prevention. Alternatives 
include trazodone, low doses of some second-generation 
antipsychotics, and some anticonvulsants.208
Consultation-liaison psychiatry
The use of BDZs in the context of consultation-liaison psy-
chiatry is relevant for several reasons. First, many patients in 
non-specialized settings of care regularly take BDZs,211 and 
consultation-liaison psychiatry may offer an opportunity to 
reduce the impact of excessive use/abuse of BDZs in the gen-
eral population.13 Second, BDZs are effective, safe (antidote 
available) and reliable, so are frequently used in the emergency 
management of all-cause agitation, and also when a detailed 
medical definition is not possible. Third, the manageability 
of BDZs gives clinicians the opportunity to use these drugs 
in medically ill patients, with complex multidrug schedules. 
Consultation-liaison psychiatry experts should advise about 
medical situations that contraindicate use of BDZs (severe 
respiratory insufficiency, myasthenia gravis) or that require 
special caution (liver and kidney disorders, elderly).212 Fourth, 
the most frequent diagnostic categories requiring psychiatric 
referral in non-specialized care settings are mild-to-moderate 
depression, anxiety disorders, and adjustment disorders, which 
are usually treated with antidepressants and BDZs.212 Fifth, 
delirium tremens is also very frequent in the general hospital 
setting, and BDZs are the first-line treatment in this context, 
but delirium tremens may be caused by BDZ withdrawal in 
patients with chronic abuse.213 Finally, BDZs are frequently 
used for self-poisoning. Consultation-liaison psychiatrists 
have to deal with both the medical complications of intoxica-
tion and the psychopathology of self-harm behaviors.
Elderly patients
BDZs are listed as potentially inappropriate drugs for use in 
late life.214 This strong recommendation is especially true for 
the long half-life BZDs. These agents should be avoided for 
the treatment of insomnia, agitation, or delirium, although 
some BDZs may be appropriate for severe GAD, sleep dis-
orders, ethanol withdrawal, seizures, peri-anesthesia proce-
dures, and end of life care.214 The anticholinergic properties 
of BDZs are especially detrimental because of side effects 
including xerostomia and constipation,215 urinary retention,216 
falls,217 and cognitive impairment.218 Recently, an increased 
risk of Alzheimer’s disease has been identified in BDZ 
users;219 however, the nature of this association, whether 
causal or otherwise, has not been established as yet and an 
appropriate surveillance system for cognitive side effects is 
suggested.220 The elderly, aged 85 years or older, pose even 
more complex medical challenges. In addition to questions on 
the appropriateness of multiple diagnostic labels and limited 
evidence of multiple disease-specific interventions,221 reduc-
tion of the overall number of prescribed drugs and avoidance 
of BDZs are recommended.214,221
In summary, use of BDZs in older adults should comply 
with at least three good clinical practice rules, ie, the short-
est treatment duration possible, preference for short half-life 
formulations, and slow titration.
Discussion
Educational needs and use of BDZs 
in clinical practice
Not surprisingly, the main finding of our review is that BDZs 
are widely prescribed in almost all psychiatric conditions, 
as well as in many other medical disorders. Prescribers 
include not only psychiatrists, but also other clinicians, such 
as primary care doctors, neurologists, oncologists, and geri-
atricians. However, too often BDZs are used off-label and 
outside recommended dose regimens, as shown in Table 4.
The reasons for such prescribing habits are likely multi-
factorial, and ultimately due to a lack of appropriate scientific 
information and effective education at multiple levels. On this 
basis, it may be speculated that the depicted scenario may not 
necessarily change in upcoming years, since psychiatrists early 
on in their careers (ie, specialists in psychiatry under 40 years 
of age and/or with less than 5 years of practice after specialty), 
in specific contexts, refer to poor education on BDZs during 
residency. Therefore, upon graduation, they may tend to 
prescribe BDZs without having adequate knowledge of their 
pharmacodynamic and pharmacokinetic properties, with a 
consequent increase in inappropriate and uninstructed pre-
scribing, unleashing clinical problems and adverse effects.
The current level of training on clinical psychopharma-
cology in psychiatric residency programs has been recently 
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investigated in surveys among trainees and early career 
psychiatrists. Respondents reported to be not fully satisfied, 
in particular to training on “old-fashioned” psychotropic 
drugs.222–224 Therefore, early career psychiatrists from Europe 
recently reported a need to improve their therapeutic arma-
mentarium, particularly as regards psychotherapeutic skills 
and traditional pharmacological compounds.12,225
Another critical area that needs to be covered by improved 
education and training is that of primary care physician 
education,226,227 being general practitioners BDZ prescribers 
as frequently as psychiatrists. In such a context, renewed 
attention from academic institutions is essential to provide 
family physicians with the psychiatrist’s clinical perspec-
tive, in order to understand respective perceptions,228 modify 
negative prescribing attitudes, and ultimately create the basis 
for subsequent collaboration and interaction.
Controversies on BDZs: between 
cautious use and false myths
BDZs differ in potency, onset of action, duration of action, 
route of administration, and pathways of metabolism, and all 
these characteristics should be taken into account by clini-
cians when prescribing a BDZ. These differences should form 
the basis for a rational choice among the various compounds 
to suit the needs of a specific clinical situation and might 
explain differences in rates of adverse effects and misuse/
dependence. Side effects of unrestricted and long-term use of 
BDZs, such as cognitive adverse events, psychomotor effects, 
paradoxical excitement/disinhibition, withdrawal symptoms, 
and dependence,8,9 may be particularly serious and should 
require an in-depth education for residents. Another area of 
major controversy in clinical practice is represented by the 
use of BDZs in pregnancy and in breastfeeding mothers.
Cognitive effects
Short-term use of BDZs can result in sedation, drowsi-
ness, mental slowing, and even anterograde amnesia.7,9 A 
systematic review of all randomized, double-blind, placebo-
controlled trials of adults undergoing detailed neuropsy-
chological testing prior to and after oral administration of 
drugs affecting the GABAergic receptor pathways found 
that BDZs provoke combined amnestic and non-amnestic 
impairments.229 Tolerance frequently occurs for sedation 
and drowsiness, while memory problems are likely to per-
sist.8 Long-term BDZ use may lead to impairments in the 
areas of verbal memory, motor control/performance, and 
nonverbal memory, but not in visuospatial skills and atten-
tion/concentration.230,231 The same study showed that these 
impairments persist well beyond cessation of BDZ use. 
However, cognitive effects, such as prolonged reaction time, 
seem to be associated only with high BDZ doses (?10 mg of 
diazepam equivalents/day).232 As prolonged reaction times 
can have adverse consequences in daily life, BDZs should 
be prescribed conservatively at the lowest possible dose.
As already specified in the section on the elderly, BDZs 
should be avoided, whenever possible, in older adults,214 who 
have an increased sensitivity to such compounds and a slower 
metabolism of long-acting agents. A major controversy 
exists, however, as to whether BDZs cause or increase the 
risk of dementia or cognitive decline. With anxiolytic use, 
oversedation can be a major problem and “pseudo-dementia” 
may develop.8 Discrepant findings emerging from studies 
examining the link between BDZ exposure and risk of cogni-
tive decline may be due to methodological differences, par-
ticularly regarding the definitions of exposure and cognitive 
outcome.233 On the one hand, an increased risk of Alzheimer’s 
disease has recently been reported,219 while results of other 
studies ruled out a strong association between BDZs and 
cognitive decline.234 Even though caution should be used in 
prescribing BDZs for older people, particularly in the long-
term, long-term BDZ use remains common in this age group: 
8.7% of elderly in the USA (aged 65–80 years) used BDZs 
in 2008, with 31.4% using them in the long term.235
Psychomotor effects
Due to sedation and impaired psychomotor skills, BDZ 
exposure can compromise driving ability. These effects are 
similar to those seen with higher blood alcohol levels and 
are potentiated by alcohol misuse.9 Growing epidemiologi-
cal evidence links therapeutic use of BDZs to an increased 
risk of traffic accidents; this implies that tolerance may 
supervene to therapeutic effects (eg, hypnotic and anxiolytic 
effects) but not so, or to a definitely lesser extent, to com-
plex perceptual and psychomotor effects.236 Again, the risk 
is higher in the elderly.7 However, the available literature 
remains unclear, with controversial results from studies using 
driving simulators;237 moreover, an increased risk of motor 
vehicle accidents is associated with all psychotropic drugs, 
not only BDZs.238 Due to drug accumulation, use of BDZs 
with a longer half-life may be more hazardous, especially 
in older people.
The elderly are particularly vulnerable to falls and frac-
tures, even with short-acting BDZs.239,240 The risk of hip 
fracture is highest during the first 2 weeks after starting a 
BDZ and declines thereafter.239 A population-based analysis 
found, however, that fracture risk in older people is increased 
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with all psychotropic medications (eg, with all drugs that may 
cause postural hypotension) and is associated, for BDZs, with 
higher doses.241 Therefore, BDZs should be cautiously used in 
elderly patients, and patients and relatives should be warned 
appropriately about the risks of use of these drugs.
Paradoxical excitement/disinhibition
Case reports of paradoxical excitement/disinhibition 
(increased talkativeness, emotional release, excitement, and 
excessive movement) and/or violence have been reported, 
raising many concerns among primary care physicians about 
whether BDZ use alone can result in disinhibited or impulsive 
behaviors.242,243 However, the overall incidence of disinhibi-
tory reactions with BDZs is small, amounting to less than 
1%.243 The risk is higher in subjects with impulse control 
problems, neurological disorders, learning disabilities, and 
in those under 18 years and over 65 years.242 Concurrent 
alcohol use, history of aggression, and underlying impulsiv-
ity (such as in BPD) may also be mediating risk factors for 
BDZ-related violence.4 It is, however, difficult to distinguish 
this possible adverse and paradoxical effect from the features 
of the underlying disorder.
Disinhibition is related to the type, dose, and route of 
administration of a BDZ.244 Preoperative intravenous admin-
istration of high doses of potent BDZs may pose a particularly 
enhanced risk.8 Useful practical steps for reducing BDZ-
related harm include: taking a comprehensive substance use 
history; avoiding prescribing BDZs (or caution in prescribing 
them) in subjects with the abovementioned characteristics; 
prescribing small quantities of BDZs for a short period of 
time at the lowest possible dose; and monitoring patients 
prescribed BDZs closely.4
Withdrawal and dependence
Withdrawal symptoms are common with BDZs, and occur on 
cessation or reduction of their use when these compounds have 
been taken repeatedly for prolonged periods of time and/or 
in high doses. In general, compounds with higher potency 
and a shorter half-life are associated with a greater likelihood 
of developing withdrawal syndromes and dependence.9 The 
mildest form of withdrawal is rebound, which means the 
original symptoms (eg, anxiety and insomnia) recur at a 
greater intensity for a period of time. Common withdrawal 
symptoms may also include physical symptoms, such as 
muscle tension and spasms, pins and needles, and flu-like 
symptoms.8 More severe or life-threatening withdrawal 
symptoms include delirium, convulsions and epilepsy and, 
occasionally, paranoid delusions.8
A significant risk of dependence is recognized in some 
patients receiving treatment for longer than one month, and 
health professionals should be aware of this when consider-
ing the relative treatment benefits and risks. However, the 
extent of the phenomenon and the reasons why some can 
withdraw without problems, even after years of continuous 
use, while others cannot remains unclear.7 In clinical studies, 
the prevalence of BDZ dependence was estimated to be as 
high as 40% among outpatients and up to 97% in those attend-
ing self-help groups.245 Population-based studies, however, 
generally report lower rates of BDZ use or misuse, but data 
on the exact prevalence of BDZ dependence are lacking. The 
potential risks of long-term treatment need to be considered 
before starting short-term treatment.9 Harm reduction should 
focus on a choice of alternative psychological and pharmaco-
logical treatments.246 If treatment courses lasting longer than 
4 weeks are required, this should not necessarily be regarded 
as a deviation from good clinical practice, although continu-
ous vigilance for potential hazards is needed throughout the 
treatment. If there is no history of drug dependence and 
positive “lifestyle” factors are present, a conscious decision 
to continue BDZ treatment may be more reasonable than 
the alternatives.9 Practical advice includes remembering that 
dependence is neither a valid reason to continue prescribing, 
nor a sufficient reason, on its own, to refuse to prescribe 
BDZs. Active consent and cooperation from the patient is 
required before attempting to reduce, gradually withdraw, or 
terminate a dependent patient’s use of BDZs; and a blanket 
refusal to prescribe BDZs without adequate assessment can 
be as problematic as prescribing them.247
Teratogenicity
Some controversies exist concerning the possible terato-
genic effects of BDZs. These compounds may rarely cause 
congenital abnormalities, mainly cleft lip/palate, when used 
during the first 3 months of pregnancy; however, discrepant 
findings emerge between cohort and case-control studies. In 
the analysis of cohort studies, fetal exposure to BDZs was 
not associated with major malformations or oral cleft. Analy-
sis of case-control studies showed an association between 
exposure to BDZs and development of major malformations 
or oral cleft alone.248 A subsequent case-control study, how-
ever, concluded that treatment with BDZs during pregnancy 
did not present detectable teratogenic risk for the fetus in 
humans.249 Of pregnant women who had babies without any 
congenital defects (population control group), 0.2% were 
treated with BDZs during pregnancy, while of those who 
delivered offspring with congenital abnormalities, 0.25% had 
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had BDZ treatment: the occurrence of BDZ treatments during 
the second and third months of gestation, ie, in the critical 
period for most major congenital abnormalities, did not show 
significant differences in matched case-control pairs.249 A 
recent critical overview concluded that data published in the 
last 10 years do not indicate an absolute contraindication to 
prescribing BDZs during the first gestational trimester.250 
Differences in the risk reported for each compound may 
explain the controversial results.
According to a systematic review, diazepam and chlordi-
azepoxide seem to be quite safe during pregnancy, clonaze-
pam and alprazolam are linked to a somewhat higher risk 
of congenital abnormalities, while lorazepam exposure is 
associated with a higher risk of anal atresia.121 As a conse-
quence, BDZs are classified differently by the US Food and 
Drug Administration: alprazolam, clonazepam, chlordiazep-
oxide, diazepam, and lorazepam are classified as category D 
(positive evidence of risk exists, but benefits from use might 
outweigh the risk), while estazolam, flurazepam, temaze-
pam, quazepam, and triazolam are classified as category X 
(contraindicated in pregnancy). When BDZs are to be used 
during the first trimester, minimizing the risk involves using 
short-acting BDZs at the lowest effective dose for the short-
est possible duration, using split doses when possible, and 
avoiding use of multiple drugs.
Decisions regarding the initiation or maintenance of 
treatment during pregnancy must reflect an understanding 
of the risks associated with fetal exposure to a particular 
medication, but must also take into consideration the risks 
associated with untreated psychiatric illness in the mother. 
Psychiatric illness in the mother is not a benign event and 
may cause significant morbidity for both the mother and her 
child.251 Discontinuing or withholding medication during 
pregnancy is not always the safest option.
Neonatal withdrawal reactions have been described,121 
so attention should be paid to women taking BDZs in the 
days immediately before delivery. In these cases, referral to 
a general hospital with appropriate neonatology assistance is 
mandatory. Neonatal BDZ exposure during breastfeeding is 
another area of possible concern, mainly related to possible 
central nervous system depression in infants; however, recent 
studies support recommendation to initiate breastfeeding 
while taking BDZs in the postpartum period, as no major 
adverse outcomes have been reported.252
Conclusion
This review outlines the state of the art on clinical use of 
BDZs in psychiatric practice and special populations of 
psychiatric patients through the contribution of young aca-
demic psychiatrists dealing with the topic according to their 
specific area of expertise. Moreover, the authors have aimed 
to critically discuss unmet needs in educational programs for 
BDZ prescribers and major controversies in BDZ use. This 
updated overview of the aforementioned issues identifies 
following key points:
?? BDZs represent a major and particularly vital chapter of 
current clinical psychopharmacology with continuous 
implications in psychiatric and medical clinical practice. 
After witnessing the golden age and the anathematiza-
tion of BDZs, it is now time to take a step forward in the 
direction of a more aware, rational, and judicious use of 
BDZs in the area of mental health.
?? BDZs may be of great clinical benefit in the short-term 
treatment of a number of psychiatric disorders, as a sole or 
combined treatment, with some exceptions representing 
relative but not necessarily absolute contraindications (eg, 
OCD and PTSD). On the other hand, the risk–benefit ratio 
in the mid term to long term is much more controversial 
and the evidence level is significantly more limited.
?? Unrestricted and unmonitored long-term use of BDZs as 
monotherapy or polytherapy should always represent a red 
flag of misuse and/or malpractice, putting the patient at 
increased risk for several side effects and adverse events.
?? Teaching and educational courses on BDZs should not 
only provide essential pillars of clinical pharmacology, 
but also practical algorithms, stemming from updated 
international treatment guidelines, to guide appropriate 
prescription of BDZs across different clinical scenarios 
and allow early detection of risk factors and potential 
indicators of misuse.
?? Clinicians and mental health professionals should be 
particularly sensitized and updated on critical situations 
that pose specific dilemmas in the clinical use of BDZs, 
including (but not restricted to) their prescription in 
pregnancy and breastfeeding, elderly patients, subjects 
with suicidal risk and substance abuse, and other special 
populations.
?? Pharmacological research should acquire renewed interest 
in the field of clinical use of BDZs in mental health through 
increased attention, firstly by academic personnel and 
teaching institutions. Support from industry and stakehold-
ers may also provide novel impetus in the investigation of 
biological and clinical correlates of BDZ use in psychiatric 
disorders.253 Since RCTs of BDZ use beyond the short 
term are largely lacking, our findings cannot be considered 
conclusive, but should rather be regarded as suggestions 
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for good clinical practice. Of course, further multicentric 
studies with longer follow-up and larger sample sizes are 
needed in order to clearly assess which factors impact on 
long-term outcomes in people taking BDZs for long peri-
ods. In addition, progressing investigation of BDZs with 
different drug-release formulations represents a promising 
developmental strategy in the field.
In conclusion, BDZs are currently neither heroes nor 
villains in psychiatric clinical practice, as the border sepa-
rating such a line is merely artificial, as spurious the debate 
concerning the possibility of an indiscriminately restricted 
use of this group of drugs. As for other hot topics in clini-
cal psychopharmacology, such as the comparison of first-
generation and second-generation antipsychotics and the 
use of antidepressants in bipolar depression, the ability to 
integrate previous knowledge with more recent evidence 
should improve the clinician’s therapeutic skills and guide 
treatment choice and monitoring, and is ultimately the most 
suitable approach for patient benefit.
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